← Back to Search

Wedge 2 for Coronavirus

N/A
Waitlist Available
Research Sponsored by Temple University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* (1) self-identified as Asian from one of the subgroups: Chinese, Korean, Vietnamese, Filipino, or other South Asian Americans
* (2) aged 18 and above
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1-month follow up, and 3-month follow up
Awards & highlights

Summary

The study aims to engage community partners to implement IMPROVE intervention and promote (COVID-19) rapid testing among vulnerable Asian Americans in the Greater Philadelphia Area and New York City

Who is the study for?
This trial is for Asian Americans in the Greater Philadelphia Area and New York City to promote COVID-19 rapid testing. Specific eligibility criteria are not provided, so it's unclear who exactly can participate.
What is being tested?
The IMPROVE intervention is being tested, which involves community partners working to increase the use of COVID-19 rapid tests among vulnerable populations.
What are the potential side effects?
Since this study focuses on promoting testing rather than a medical treatment or drug, there are no direct side effects from interventions like those seen with medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1-month follow up, and 3-month follow up
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1-month follow up, and 3-month follow up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
the change in the rate of COVID-19 self-testing

Trial Design

3Treatment groups
Experimental Treatment
Group I: Wedge 3Experimental Treatment1 Intervention
The wedge 3 group started the intervention in the study months 10-15.
Group II: Wedge 2Experimental Treatment1 Intervention
Following the wedge 1 group, the wedge 2 group started the intervention in the study months 7-12.
Group III: Wedge 1Experimental Treatment1 Intervention
The earliest group to implement the IMPROVE intervention ( in 4-9 study months).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IMPROVE
2016
N/A
~1010

Find a Location

Who is running the clinical trial?

Temple UniversityLead Sponsor
304 Previous Clinical Trials
85,394 Total Patients Enrolled
National Institute on Minority Health and Health Disparities (NIMHD)NIH
397 Previous Clinical Trials
1,343,120 Total Patients Enrolled
~0 spots leftby Sep 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top